The effect of geranylgeranylacetone on human osteoclastogenesis and synovitis in patients with rheumatoid arthritis

Yuki Nanke*, Shigeru Kotake, and Naoyuki Kamatani
Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with synovitis and bone destruction. The levels of monocyte/macrophage-derived cytokines, including TNFα, interleukin-1 (IL-1), and IL-6, and the T cell-derived cytokine, IL-17, all of which are involved in the pathogenesis of RA, are elevated in the synovial fluid of RA patients.

Geranylgeranylacetone (GGA), an acyclic polyisoprenoid known as teprenone, has been widely used as an antiulcer drug. We have reported that GGA inhibits human osteoclastogenesis, and that GGA increases the bone mineral density in ovariectomized rats and tail-suspended rats. These effects are due to inhibiting the prenylation of geranylgeranylpyrophosphate (GGPP) by GGA in the mevalonate pathway. Recently, we also demonstrated that GGA induces cell death in fibroblast-like synoviocytes from patients with RA. These findings suggest that GGA may be available as a new agent for RA and osteoporosis.


* Correspondence should be addressed to:
Dr. Yuki Nanke, Institute of Rheumatology, Tokyo Women's Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan. Tel: +81-3-5269-1725, Fax: +81-3-5269-1726, e-mail: ynn@ior.twmu.ac.jp

Key words apoptosis, geranylgeranylation, rheumatoid arthritis, synovitis, statin

Introduction

RA is a chronic inflammatory disease characterized by the synovitis1) and the destruction of articular cartilage and bone. The levels of monocyte/macrophage-derived cytokines, including TNFα, interleukin-1 (IL-1), and IL-6, and the T cell-derived cytokine, IL-17, all of which are involved in the induction of osteoclasts, are elevated in the synovial fluid of RA patients, suggesting that cytokine-mediated osteoclastogenesis occurs in the joints2,3).

Statins, 3-hydroxy-3-methylglutary-CoA reductase inhibitors, are widely used to treat hyperlipidemia. In addition to their beneficial lipid-lowering effects, statins have shown to have pleiotropic effects4,5) in various systems such as the immune system, cardiovascular system, nervous system and skeletal system6,7). In particular, the immunosuppressive effect of statins has been highlighted. Statins improve endothelial function, decrease oxidative stress and inflammation. In vitro studies have shown that statins suppress natural killer cells, regulate DNA synthesis in cycling cells and inhibit monocyte chemotaxis. Thus, statins might be used as an immunomodulator in autoimmune diseases
such as RA. In fact, atorvastatin and simvastatin have anti-inflammatory effect with patients with RA\textsuperscript{8,11}. Many of these effects are related to the inhibition of isoprenoid synthesis, which serves as lipid attachment for small G proteins implicated in intracellular signaling. These small G proteins, whose proper membrane localization and function depend on isoprenylation, play an important role in the pleiotropic effects of statins\textsuperscript{12-14}. Recently, fluvastatin (Fluv) has been reported to induce apoptosis in RA synoviocytes through the blocking of protein geranylgeranylation\textsuperscript{15}.

We recently demonstrated that geranylgeranylnacetone (GGA)\textsuperscript{16,17} potently inhibit the human osteoclastogenesis induced by soluble receptor activator of nuclear factor-κB ligand (sRANKL)\textsuperscript{18-21}. These effects were due to inhibition of the function of geranylgeranylnyrophosphate (GGPP) in the mevalonate pathway. Thus, small G protein also plays an important role in the pleiotropic effects of GGA. Moreover, GGA prevents bone loss in ovariectomized (OVX) rats and tail-suspended rats \textit{in vivo}\textsuperscript{18}. In addition, we also reported that GGA induces cell death in RA synoviocytes.

In this mini review, we describe the effect of GGA on osteoclastogenesis and the anti-inflammatory effect on RA, as well as introducing some other pleiotropic effects.

### Chemical structure of GGA

As shown in Figure 1, GGA has almost the same chemical structure as the side chain of menatetrene, vitamin K\textsubscript{2}. GGA, an acyclic polyisoprenoid, has been widely used as an antilulcer drug since 1984. GGA increases the synthesis and secretion of gastric mucin as well as the components of high molecular-weight glycoproteins and surface-active phospholipids\textsuperscript{22,23}.

![Chemical structure of GGA and menatetrene](image)

**Fig.1 Chemical structures of GGA and menatetrene**  
GGA has almost the same chemical structure as the side chain of menatetrene. (Modified from Nanke et al: Calcif Tissue Int, 77: 376-385, 2005.)

---

**The role of GGA in human osteoclastogenesis \textit{in vitro}**

GGA (500-1000 ng/mL) dose-dependently inhibited the formation of osteoclasts from human monocytes induced by sRANKL\textsuperscript{19}. GGA induced degradation of actin rings in mature osteoclasts at pharmacological concentrations.

**GGA blocks the function of GGPP in the mevalonate pathway**

The degradation of actin rings of osteoclasts induced by GGA (1000 ng/mL) was reversed by GGPP (10 μM) but not by farnesylpyrophosphate (FFP)\textsuperscript{18}. Thus, GGA blocked the function of GGPP by competitive inhibition of the mevalonate pathway (Fig.2).

**Effect of GGA on ovariectomized (OVX) and tail-suspended rats**

GGA increased the bone mineral density (BMD) of the total femur, proximal metaphysis and diaphysis of the femur in OVX rats. GGA also prevents bone loss induced by hindlimb unloading in tail-suspended rats. GGA increased histological bone volume in both OVX rats and tail-suspended rats. These findings suggest that GGA is available as a new agent for osteoporosis.

**The effect of GGA in fibroblast-like synoviocytes from patients with RA**

Since Fluv induces apoptosis in RA synoviocytes by inhibiting protein geranylgeranylation in the mevalonate pathway, we
Table 1a Pleiotropic effect of GGA (1)

<table>
<thead>
<tr>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>GGA induces overexpression of the heat shock protein in various organs</td>
<td></td>
</tr>
<tr>
<td>Human gastric mucosa</td>
<td>Yanaka et al 24)</td>
</tr>
<tr>
<td>Guinea pig gastric mucosal cells</td>
<td>Takano et al 25), Hirakawa et al 26)</td>
</tr>
<tr>
<td>Rat gastric mucosa</td>
<td>Hirakawa et al 26)</td>
</tr>
<tr>
<td>Heart</td>
<td>Shinohara et al 27), Yamanaka et al 28)</td>
</tr>
<tr>
<td>Kidney</td>
<td>Suzuki et al 29)</td>
</tr>
<tr>
<td>Liver</td>
<td>Ochikawa et al 30), Fudaba et al 31)</td>
</tr>
<tr>
<td>Retina</td>
<td>Kitanei et al 32)</td>
</tr>
<tr>
<td>GGA protects against ischemic/reperfusion injury</td>
<td>Hirakawa et al 26), Ooie et al 33)</td>
</tr>
<tr>
<td></td>
<td>Harada et al 34)</td>
</tr>
</tbody>
</table>

Table 1b Pleiotropic effect of GGA (2)

<table>
<thead>
<tr>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>GGA induces protective porteins</td>
<td></td>
</tr>
<tr>
<td>Neuronal nitric oxide(NO) synthase</td>
<td>Nishida et al 35), Fujiki et al 36)</td>
</tr>
<tr>
<td>Apoptosis</td>
<td>Endo et al 37)</td>
</tr>
<tr>
<td>protein kinase C</td>
<td></td>
</tr>
<tr>
<td>Central nervous system</td>
<td>Uchida et al 38)</td>
</tr>
<tr>
<td>Gastric mucosa</td>
<td>Rokutan et al 39)</td>
</tr>
<tr>
<td>Myocardium</td>
<td>Yamamoto et al 40), Yamanaka et al 28)</td>
</tr>
<tr>
<td>Liver</td>
<td>Hirota et al 41)</td>
</tr>
<tr>
<td>Cochlea</td>
<td>Sone et al 42)</td>
</tr>
<tr>
<td>Brain</td>
<td>Yenari et al 43)</td>
</tr>
</tbody>
</table>

Table 1c Pleiotropic effect of GGA (3)

<table>
<thead>
<tr>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>GGA inhibits cancer invasion</td>
<td>Hashimoto et al 44)</td>
</tr>
<tr>
<td>GGA induces COX-2 expression and incresed PGE(2) production via activation of the nuclear factor-kappaB sites of COX-2 gene promotes</td>
<td>Yenari et al 43), Nishida et al 45), Wojcik et al 46)</td>
</tr>
<tr>
<td>GGA is a novel therapy for artial fibrillation</td>
<td>Brundel et al 47)</td>
</tr>
<tr>
<td>GGA has an effective on gentamycin ototoxicity in rat cochiler culture</td>
<td>Sano et al 48)</td>
</tr>
<tr>
<td>GGA has antiviral effect that enhances MxA expression and phoshorylation of PKR during influenza virus infection</td>
<td>Unoshima et al 49)</td>
</tr>
</tbody>
</table>

hypothesized that GGA also induces cell death in fibroblast-like synoviocytes (FLS) from patients with RA by inhibiting protein geranylgeranylation. Synovial tissues were obtained from patients with RA at the time of total knee arthroplasty. FLS in 3 passages were cultured with various concentrations of GGA (0.1-4.0 mg/ml) and 0.1 and 0.5 μM of Fluv for 48 hours. We also examined the effect of GGA and Fluv in human fibroblasts from skin (CCD-25SK). The number of cells demonstrating cell death was counted by trypan blue staining. In the absence of GGA, there was no apparent cell death on trypan blue staining. The concentration of 0.1-4.0 mg/ml GGA induced cell death in RA synoviocytes. The number of synoviocytes demonstrating cell death
death induced by 0.1 and 0.5 μM of Fluv was significantly higher compared with that by medium alone. Neither GGA (0.1-4.0 μg/ml) nor Fluv induces cell death of fibroblasts from skin (data not shown).

We demonstrated that GGA induced cell death in FLS from patients with RA, but not in skin fibroblasts. We showed a marked reduction in RA synovial FLS survival though the induction of cell death when the cells were cultured with GGA (100-4000 ng/ml). As reported recently, Fluv also induced cell death[13]. We have previously demonstrated that GGA potently inhibits human osteoclastogenesis induced by sRANKL and induces degradation of actin rings in mature osteoclasts in vitro as well as preventing bone loss in both ovariecetomized rats and tail-suspended rats in vivo[14-22]. GGPP reversed the GGA-induced degeneration of the actin rings of osteoclasts. Thus, GGA blocked the functions of GGPP by competitive inhibition of the mevalonate pathway.

Pleiotropic effect of GGA and statins

Klinderer et al reported that statin-induced expression of CD56 on vascular endothelium under hypoxia is a potent mechanism for the anti-inflammatory action of statin in RA[26]. Thus, these finding suggests that statins would be a useful immunomodulator in autoimmune diseases such as RA. In fact, atrovastatin and simvastatin have shown anti-inflammatory effects in patients with RA[13].

Many of these effects are related to the inhibition of isoprenoid synthesis, which serves as a lipid attachment for small G proteins implicated in intracellular signaling. These small G proteins, whose proper membrane localization and function depend on isoprenylation, play an important role in the pleiotropic effects of statins[7-12,14]. In fact, Fluv has been reported to induce apoptosis in RA synoviocytes through the blocking of protein geranylgeranylation[15]. RhoA plays a role as the key regulator of TNFα-induced NF-κB activation, which ultimately results in the secretion of proinflammatory cytokines in RA synoviocytes[15]. This small G protein also plays an important role in the anti-inflammatory effect of GGA in RA. Table 1 shows other pleiotropic effects of GGA.

In summary, the recent study clearly demonstrated that GGA induced cell death in RA synoviocytes and had an anti-inflammatory effect. GGA is known to induce HSP, COX-2 and protein C and protect cell from ischemia and reperfusion injury. We previously reported that GGA inhibits human osteoclastogenesis[18]. Thus, GGA has therapeutic implications in RA by reducing synovitis, inflammation, bone destruction and osteoporosis.

Acknowledgement

We thank you for Prof. Toshikazu Yoshikawa for useful discussion at the 28th of JAPAN congress of Inflammation and Regeneration in Tokyo, August 2007.

References

10) Jansen TL: Atorvastatine for chronic synovitis due to mas-


